Clinical Trial

Deployment and Evaluation of Artificial Intelligence Software for Electrocardiogram Analysis and Management in Primary Care

Study acronym: DAISEA-ECG
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The DAISEA-ECG project aims to improve the diagnosis of heart diseases in primary care through the DeepECG platform, which combines ECG-AI and ECHONeXT algorithms. This study uses a stepped wedge design, where each Family Medicine Group acts as its own control. The FMGs will gradually transition from the control period (without AI recommendations) to the intervention period (with AI recommendations activated) in a randomized sequence. The primary objective is to compare the sensitivity of family physicians in detecting cardiac pathologies, with and without the assistance of the DeepECG platform. Sensitivity is defined as the proportion of patients correctly referred to cardiology or for transthoracic echocardiography (TTE) among those who indeed required cardiovascular evaluation, as confirmed by an independent adjudication committee.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-10-09.
Trial Details
NCT Number NCT06637293
Lead Sponsor Montreal Heart Institute
Conditions Primary Care Provider, Structural Heart Disease
Enrollment 2,000 participants
Start Date 2025-10-06
Primary Completion 2027-01 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2025-09-19